Diabetology Xagena

Xagena Mappa
Xagena Newsletter

Statins may protect against microvascular complications of diabetes mellitus

The development of common diabetes complications that can lead to blindness and amputations could be reduced by taking statins, indicates new research published in The Lancet Diabetes & Endocrinology.

It is well established that statins via cholesterol lowering effectively reduce the risks of myocardial infarction and stroke in people with type 2 diabetes mellitus, but whether statin use affects the development of small blood vessel ( or microvascular ) complications, such as eye, nerve, and kidney disease in individuals with diabetes is not known.

Using whole-country data from Danish clinical registries, the investigators examined whether statins reduced the incidence of microvascular complications in more than 60 000 individuals selected at random from all patients with diabetes in the entire national population who were aged 40 years or older and diagnosed during the period 1996-2009.
The microvascular outcomes of 15 679 patients who had used statins regularly before their diabetes diagnosis were compared with 47 037 patients who had not used statins prior to diagnosis.

Results showed that over a median follow-up of 2.7 years ( maximum 13 years ), people who used statins were 34% less likely to be diagnosed with diabetic neuropathy ( nerve disease that can lead to foot problems that require amputation ), 40% less likely to develop diabetic retinopathy ( damage to the retina that can lead to blindness ), and had a 12% reduced risk of gangrene compared to those who had not received statins.
However, the risk of diabetic nephropathy was similar between the groups.

Statin users were also slightly more likely to be diagnosed with diabetes, as shown in previous studies.

Researchers found no evidence that statin use is associated with an increased risk of microvascular disease. Whether or not statins are protective against some forms of microvascular disease, a possibility raised by these data, and by which mechanism, will need to be addressed in randomised controlled trials.

According to David Preiss from the British Heart Foundation Cardiovascular Research Centre at the University of Glasgow in the UK, statins act by reducing circulating LDL cholesterol and, to a lesser extent, triglycerides. But if statins do protect from microvascular damage, their effect might have little to do with lipid modification.
Fibrates are other lipid-modifying agents which have shown promising results for lowering the progression of retinopathy, but this appears to be due to direct anti-inflammatory effects in the eye rather than lipid modification.
Statins also have anti-inflammatory effects which might slow the progression of microvascular disease in the eye or kidney. For now, however, any benefit of statins on microvascular complications remains unproven. ( Xagena )

Source: The Lancet, 2014